http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#Head
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#assertion
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#provenance
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#pubinfo
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#assertion
http://purl.obolibrary.org/obo/DOID_14330
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_14330
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00413
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
http://www.w3.org/2000/01/rdf-schema#label
mirapex r pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease the effectiveness of mirapex tablets was demonstrated in randomized controlled trials in patients with early parkinson s disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa see clinical studies mirapex tablets are indicated for the treatment of moderate to severe primary restless legs syndrome rls key diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with symptoms of rls
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00413
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#provenance
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#pubinfo
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig
http://purl.org/nanopub/x/hasSignature
GN4KrmT1rluDJrEveV8UvSW1Wo3+mYqwoTWmdrxfwDCBLN2Vw0EkGCeeVRzFKEVXr5h4/b1gQuprBYlkLMvX780tW02Gl4tlfIM1nse2Bd0FHpL1V5kC/e9il6Vhib74P1x5nBne8zYtv+7n+FNV6hBpzCeKqX5ADKBfiZgThN8=
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://purl.org/dc/terms/created
2021-06-30T09:10:36.868+02:00
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs